Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

General (Details Narrative)

v3.20.2
General (Details Narrative) - USD ($)
12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Jun. 15, 2020
Feb. 27, 2019
Dec. 31, 2016
Accumulated losses $ (17,507,868) $ (5,693,353)        
Working capital 1,535,491          
Shareholders' deficit (6,248,812) (1,215,934) $ (1,339,633)     $ (403,949)
Cash and cash equivalents 12,155 63,550        
Convertible Bridge Loans Transactions [Member]            
Proceeds from issuance of financial instruments 1,374,470 27,000 226      
Exercise of Stock Warrants into Shares [Member]            
Proceeds from issuance of financial instruments   324,258 599,400      
Private Placement Transactions [Member]            
Proceeds from issuance of financial instruments $ 295,000 $ 100,000 $ 562,604      
Subsequent Event [Member]            
Cash and cash equivalents       $ 300,000    
Joint Venture Agreement [Member] | Breakthrough Diagnostics, Inc. [Member]            
Ownership percentage         19.99%